论文部分内容阅读
目的评价利培酮口服液和奎硫平治疗脑血管病所致精神障碍的疗效和安全性。方法将62例脑血管病所致精神障碍患者随机分成两组,分别给予利培酮口服液和奎硫平治疗,疗程为6周。采用简明精神病量表(BPRS)评定疗效,副反应量表(TESS)评定不良反应。结果利培酮口服液和奎硫平治疗脑血管病所致精神障碍均有效且起效快,1周末活动过多因子分较治疗前比较差异具有统计学意义(P<0.05),2周末BPRS总分和其他因子分较治疗前,6周末比较差异具有明显统计学意义(P<0.01),两种药物间疗效无显著性差异。两组不良反应均较少且轻微,不良反应发生率差异无统计学意义(P>0.05)。结论利培酮口服液与奎硫平疗效相似,均是治疗脑血管病所致精神障碍安全有效的药物。
Objective To evaluate the efficacy and safety of risperidone oral solution and quetiapine in the treatment of mental disorders caused by cerebrovascular disease. Methods Sixty-two patients with mental disorders caused by cerebrovascular disease were randomly divided into two groups, and were given risperidone oral solution and quetiapine respectively for 6 weeks. The curative effect was assessed by the Simple Mental Illness Scale (BPRS), and adverse reactions were assessed by the TESS. Results Risperidone oral solution and quetiapine were effective and rapid onset of treatment for mental disorders caused by cerebrovascular disease. Excessive activity after 1 week had a significant difference compared with that before treatment (P <0.05). BPRS The difference between the total score and other factors before and 6 weeks was statistically significant (P <0.01). There was no significant difference between the two drugs. Two groups of adverse reactions were less and less, the incidence of adverse reactions was no significant difference (P> 0.05). Conclusions Risperidone oral solution and quetiapine have similar therapeutic effects, which are both safe and effective in the treatment of mental disorders caused by cerebrovascular disease.